GlassScriptPhysician profile
Kyle D Groshans
NPI 1336751627
$9,664.20
in general payments reported to CMS, 2019-2025
29 companies · $2,165 in 2025
The $2,165 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,988 · 2022: $3,036 · 2023: $275 · 2024: $201 · 2025: $2,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,493 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,493.27 |
| Education | $146.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,478.21 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,347.43 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $707.46 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $667.27 | 2021-2022 | |
| Alkermes, INC. | $648.03 | 2021-2022 | |
| Lundbeck LLC | $646.45 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $628.94 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $574.33 | 2021-2025 | Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $433.44 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $383.67 | 2021-2025 | Invega, Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $337.88 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Jazz Pharmaceuticals INC. | $272.82 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $214.86 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $211.21 | 2024-2025 | Auvelity |
| Almatica Pharma LLC | $163.44 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $143.13 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $141.22 | 2022-2025 | Qelbree |
| Indivior INC. | $133.61 | 2021-2025 | Sublocade |
| Bausch Health US, LLC | $127.03 | 2021-2022 | |
| Biogen, INC. | $103.02 | 2025 | Zurzuvae |
| Braeburn INC. | $75.61 | 2025 | Brixadi |
| Biohaven Pharmaceuticals, INC. | $66.62 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.76 | 2022 | |
| Eisai INC. | $39.60 | 2021 | |
| Allergan, INC. | $22.90 | 2021 | |
| Sk Life Science, INC. | $17.61 | 2022 | |
| Owp Pharmaceuticals, INC. | $14.08 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.16 | 2022 | |
| Noven Therapeutics, LLC | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Groshans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.